Ultragenyx Pharmaceutical (RARE) Operating Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has reported Operating Leases for 7 consecutive years, with $24.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Leases fell 20.0% year-over-year to $24.0 million; the TTM figure through Dec 2025 stood at $24.0 million (down 20.0% YoY), while the FY2025 annual figure was $24.0 million, down 20.0% from the prior year.
• Operating Leases improved to $24.0 million in Q4 2025 per RARE's latest filing, from $21.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $36.8 million in Q1 2021 and bottomed at $14.8 million in Q2 2023.
• Historically, Operating Leases has averaged $26.8 million across 5 years, with a median of $26.8 million in 2022.
• Annual changes were most pronounced in 2023 — Operating Leases sank 42.69% — and 2024, when it jumped 73.4%.
• Ultragenyx Pharmaceutical's Operating Leases stood at $30.9 million in 2021, then sank by 35.89% to $19.8 million in 2022, then jumped by 54.31% to $30.6 million in 2023, then declined by 1.88% to $30.0 million in 2024, then slipped by 20.0% to $24.0 million in 2025.
• Business Quant data shows RARE's Operating Leases at $24.0 million in Q4 2025, $21.7 million in Q3 2025, and $24.5 million in Q2 2025.